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HybridRanker: Integrating network structure and disease knowledge 
to prioritize cancer candidate genes 
 
One of the notable fields in studying the genetics of cancer is disease gene identification 
which affects disease treatment and drug discovery. Many researches have been done in 
this field. Genome-wide association studies (GWAS) are one of them that focus on the 
identification of diseases-susceptible loci on chromosomes. Recently, computational 
approaches, known as gene prioritization methods have been used to identify candidate 
disease genes. Gene prioritization methods integrate several data sources to discover and 
prioritize the most probable candidate disease genes. In this paper, we propose a 
prioritization method, called HybridRanker which is a network-based technique and it 
also uses experimental data to identify candidate cancer genes. We apply our proposed 
method on colorectal cancer data. It is notable to say that in HybridRanker, for 
considering both local and global network information of a protein-protein interaction 
network, different algorithms such as shortest-path, random walk with restart and 
network propagation are exploited. By using these algorithms, initial scores are given to 
genes within the network. Furthermore, by looking through diseases with similar 
symptoms and also comorbid diseases and by extracting their causing genes, the gene 
scores are recalculated. We also use gene-phenotype relations for an additional scoring of 
the candidate genes. Our method is validated and compared with other prioritization 
methods in leave one-out cross-validation and the comparison results show the better 
performance of the HybridRanker. 
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1.   Introduction 
Cancer is one of the leading causes of death in the world. The early diagnosis of cancer 
may prevent the spread of it to other parts of the body and reduce early death risk. So, 
discovering cancer causing genes is a crucial topic in studying the genetics of cancer. 
Linkage analysis is an experimental approach to explore diseases-susceptible loci on 
chromosomes. But, experimental explorations are both time consuming and expensive 
and are not always feasible [1]. More feasible approaches for this problem are 
computational ones, known as gene prioritization methods. Prioritization methods 
leverage experimentally verified disease genes to identify new candidate disease genes 
for further analysis. To obtain more reliable results, these methods usually integrate 
different information from several available sources, such as sequence properties, 
functional annotations, transcriptomic data, molecular pathways, protein-protein 
interactions and literatures [2-5]. 
A number of studies collected biomedical keywords of known disease genes and used 
text-mining techniques to rank candidate genes based on the text similarity [6, 7]. In 
some other researches, basic knowledge such as Gene Ontology (GO) or sequence 
similarity were gathered to construct similarity profiling and they scored candidate genes 
using this similarity profiling [2, 4, 8].  
Under the assumption that the genes cause the same disease, tend to have physical 
interactions with each other or participate in the same functional pathways, protein-
protein interaction (PPI) networks are important sources for gene prioritization problem 
and their integration with other data helps to identify more reliable cancer-causing genes. 
Early network-based prioritization methods like molecular triangulation [9], shortest-path 
(SP) [10] and direct neighbors [11] focus on network local information which lead to 
vulnerable results. To improve the performance of these prioritization methods, other 
techniques such as random walks with restart (RWR) [12] and network propagation (NP) 
[13] utilized network global information. We remark that one of the deficiencies of the 
later approaches is ignoring genes with few connections in the PPI network [14].  
To overcome the disadvantages of aforementioned methods, we propose a new approach, 
called HybridRanker, which benefits from both local and global information of the 
network. Additionally, in developing our method we use the assumption that disease 
comorbidity and the similarities in symptoms and phenotypes are arisen from common 
 molecular mechanisms [15-18]. Because of all mentioned reasons, we composed RWR, 
SP and NP algorithms in HybridRanker and also exploited genetic data of diseases with 
similar symptoms and similar phenotypes, and comorbid diseases as well. All these made 
our approach a hybrid method based on both network structure and biological knowledge. 
As colorectal cancer (CRC) is the third most common type of cancer and one of the major 
cause of mortality in the world [19, 20], we applied HybridRanker on CRC data. For 
evaluating the performance of the HybridRanker, it was validated and compared with 
other prioritization methods in leave one-out cross-validation analysis. The results have 
shown the better performance of HybridRanker. 
 
2.   Material and Methods 
2.1.   Disease genes prioritization  
Network topology is a crucial issue in gene prioritization methods. In a given network, 
local information of a node relates to the topological neighborhood of that node, while 
global information characterizes the role of that node within the whole network [14]. In 
HybridRanker, we utilized both local and global information of the network to improve 
the performance of previous methods. We applied SP algorithm to extract local 
information within the network and for obtaining global information of the network, 
RWR and NP algorithms were used. Initially we scored all proteins within the network 
by these three algorithms. Furthermore, we exploited the information about disease 
similarity, comorbidity and phenotype similarity in our method. These steps are described 
in the following sections: 
 
RWR algorithm 
 
By using RWR algorithm all proteins within a given network were ranked based on their 
proximity to seed genes. Random walks in this algorithm started at seed genes and in 
each iteration, with a given probability, went to the neighbors of the current nodes or 
restarted at seed genes. The final ranking was computed by the steady state probability 
vector of these random walks. In each iteration, the probability vector was calculated by: 
𝑃𝑡+1 = (1 − 𝑟)𝑊𝑃𝑡 + 𝑟𝑃0 (1) 
where 𝑟 was set to be the restart probability, 𝑊was the weighted adjacency matrix of the 
given network with normalized columns. 𝑃0 was the vector of primary probabilities of 
nodes and 𝑃𝑡 contained the probabilities of being at each node in the 𝑡-th iteration. 
Initially, in our method, equal probabilities were assigned to all seed genes and other 
genes were given zero probability. We tested RWR with different values of 𝑟 and the best 
accuracy was obtained at 𝑟 = 0.15. The steady state was achieved by performing 
iterations until the difference between two consecutive probability vector (𝑃𝑡 and 𝑃𝑡+1) 
became less than 10−6(the difference ismeasured by 𝐿1 norm) [12]. 
 
Network propagation algorithm (NP)  
 
NP algorithm is very similar to the RWR algorithm and it also uses network flow 
propagation to prioritize genes. In RWR, the adjacency matrix is also normalized but in a 
different way. In NP algorithm both input and output flows of nodes are normalized, in 
the other words, rows are also normalized in the adjacency matrix [13]. NP algorithm was 
used to give a rank to each protein in the PPI network. 
 
SP algorithm 
 
In addition to previous steps, proteins within the network were ranked with respect to 
their shortest-path distance to seed ones. The shortest-path distance between seed genes 
and all other genes were calculated by Dijkstra [21] algorithm. For each non-seed gene, 
its minimum shortest-path distance to the seed genes was used for its ranking. It was 
assumed that being close to a seed gene would be a good evidence for a gene to be 
associated with that disease [22]. 
 
Disease similarity information 
 
To explore disease with similar symptoms, Human Symptoms Disease Network (HSDN) 
[23] was used. There were 36 diseases in HSDN which shared similar symptoms with 
CRC. The causing genes of these diseases were extracted from DisGeNET [24] database. 
It is possible that diseases with similar symptoms arise because of sharing common 
disease genes. To consider the similarity of disease symptoms in scoring causing genes, 
initially all genes were given “zero” score. Iteratively, we went through each similar 
 disease with CRC and the score of its causing genes were added by one. Finally, the score 
of a gene showed the number of similar (in term of symptoms) diseases it was associated 
with. For instance, if a gene was a common causing gene of four similar diseases, its final 
score would be four. The higher score a gene is given, the more likely this gene is CRC-
related. So, genes with higher scores were ranked better.  
We selected both the top ten and the top five most similar diseases for scoring genes and 
the better accuracy was achieved when the top ten similar diseases were used. These ten 
diseases are listed in Table 1. 
 
 
Table 1. The ten most similar diseases to CRC based on their symptoms (extracted from HSDN). 
 
Disease Symptom similarity score 
Fibrous Dysplasia, Polyostotic 0.971 
Port-Wine Stain 0.749 
HIV Infections 0.746 
Breast Neoplasms, Male 0.599 
Ileitis 0.526 
Esophageal Neoplasms 0.443 
Neoplastic Syndromes, Hereditary 0.422 
Leukemia, Myeloid, Acute 0.421 
Microcephaly 0.295 
Hyperlipidemias 0.380 
 
 
 
Disease comorbidity information 
We explored MalaCards [25] database for comorbid diseases with CRC (in April 
2015) and then their causing genes were extracted from DisGeNET database (six 
comorbid diseases with CRC are shown in Table 2). Finally, to exploit comorbidity 
information in HybridRanker, genes were scored in the similar way as stated in the 
previous step. 
 
 
Table 2. Comorbid diseases with CRC (extracted from MalaCards database). 
 
Disease name 
Adenoma 
Breast Cancer 
HIV Infections 
Familial adenomatous polyposis 
Lunch-Syndrom 
Ovary Cancer 
 
 
 
Gene-phenotype information 
 
All different symptoms of CRC were extracted from HSDN and they are shown in Table 
3. For each CRC symptom, genes causing similar phenotype were found through 
PhenomicDB [26]. Again, the similar scoring process which was used in the two previous 
steps was repeated for scoring genes based on gene-phenotype information. 
 
Table 3. Human phenotypes related to CRC (extracted from HSDN). 
 
Symptoms for CRC Score 
Obesity 81.59026 
Cachexia 29.92086 
Weight Loss 29.00156 
Body Weight 18.17836 
Weight Gain 10.40683 
Fever 7.427252 
Overweight 7.414849 
Asthenia 6.189658 
Birth Weight 5.628524 
Fetal Macrosomia 3.336718 
 
 As we mentioned before, there were six different scoring schemes utilized in 
HybridRanker. To prioritize genes based on these six scores, a simple summation of them 
was used. 
2.2.   Data extraction 
We used the human PPI network created by Lage et al. [27] which is an undirected 
weighted network. Interactions are extracted from different large scale data sources and 
their weights are based on network topology and experimental evidences. For noise 
reduction within the network, a cutoff threshold of 0.154 was defined for interaction 
weights. The filtered network contained 12,884 nodes (proteins) and 428429 edges 
(interactions). 
CRC disease genes were extracted from DisGeNET which contains experimentally 
validated disease genes. By mapping CRC disease genes to the PPI network, 1121 genes 
in the network were marked as seed genes. 
We explored MalaCards database for comorbid diseases and used HSDN to find diseases 
with similar symptoms. Also, genes with similar phenotype were extracted from 
PhenomicDB database. 
 
2.3.   Comparison to other methods 
Leave-one-out cross-validation analysis was used to evaluate the HybridRanker and then 
its performance was compared with the performance of some other prioritization 
methods. Endeavour [28], ToppGene [4] and DIR [5] were three prioritization methods 
which their performances were compared with that of HybridRanker. 
In each validation step, one seed gene was selected as a target gene and removed from the 
seed gene set. Then, we made an artificial linkage interval (containing 100 genes) with 
this target gene and its 99 nearest chromosomal neighbors (the chromosomal neighbors 
were obtained from UCSC database [29]). The remaining seed genes made a new seed 
gene set and the HybridRanker was applied on it. So, all the genes in the artificial linkage 
interval were given ranks based on the new seed gene set. The ranking of the target gene 
amongst other genes in the artificial linkage interval was the criterion for the performance 
evaluation. In other words, the higher rank the target gene is obtained, the better 
performance the algorithm has [12]. To show the performance of our method, receiver 
operating characteristic (ROC) curve was drawn to plot sensitivity versus 1-specificity. 
Also, for better evaluation, the area under curve (AUC) was calculated for each curve. 
Here, the specificity was defined by the percentage of target genes (selected from the 
seed genes) ranked below a specific threshold and the sensitivity was the percentage of 
target genes which were ranked above that threshold. 
For further evaluation of the HybridRanker, mean reciprocal rank (MRR) was used which 
is defined by: 
MRR =
1
|Q|
∑
1
ranki
|Q|
i=1                                                 (2) 
where 𝑄 shows the number of artificial linkage intervals and 𝑟𝑎𝑛𝑘𝑖  was the ranking of i
th
 
removed seed gene in its related interval.  
Also, we defined an average rank criterion which was calculated by averaging the ranks 
of all seeds in their corresponding intervals. The lower average rank shows the better 
performance of the algorithm. Also, the notations 1% and 5% were used to show the 
percentage of seed genes those were respectively ranked in the top 1% and 5% of their 
related intervals. All aforementioned criteria were computed for evaluating different 
methods. 
2.4.   Gene Set Enrichment Analysis 
To examine the biological relevance of our result genes and CRC, we gave the top 100 
ranked candidate genes as input for ClueGO, a Cytoscape plug-in, to integrate GO terms 
and pathway annotations. For pathway enrichment analysis, the KEGG, Wikipathways 
and Reactome databases which have been embedded in ClueGO plug-in were employed.  
 
3.   Results 
We utilized a PPI network, with 12894 gens (proteins) in which 1121 nodes were labeled 
as seed genes based on experimentally examined causing genes of CRC. The SP 
algorithm (a method based on network local information), RWR and NP algorithms 
(methods based on network global information) were used to calculate the proximity of 
other nodes to the seed nodes. We used these three algorithms simoultansly to benefit 
both network local and global information. As it is shown in Figure1, the combination of 
network-based algorithms with biological knowledge (which resulted in the 
HybridRanker) had better perfomance than using only these three network-based 
algorithms. 
  
 
Figure 1. The NP, RWR and SP algorithms were applied on the PPI network and a combination of their scores 
was assigned to each gene. This figure shows the ROC curves for this combination and HybridRanker. In 
HybridRanker aforementioned algorithms were also composed with disease knowledge [23, 25, 26]. 
 
Also, for each network-based algorithm and each biological knowledge used in the 
HybridRanker, we evaluated their ability to prioritize genes. The results showed that 
neither of them is as powerful as the HybridRanker (see Figure 2). 
 
Figure 2. The ROC curves for HybridRanker and other scorings which are used in it. 
 We compared our proposed method with well known tools such as DIR, Endeavour and 
ToppGene which each has utilitized different data sources to prioritize genes. The ROC 
curves were drawn for each method (shown in Figure 3) and their AUC were also 
calculated (shown in Table 4). As it is shown in Table 4, the HybridRanker resulted in 
AUC of 0.95 which had the best performance among all examined methods. The NP and 
DIR methods were ranked as the second best methods with AUC of 0.91. Also, the 
average rank (See comparison to other mthods section) of the HybridRanker was 5.28 
while for DIR, NP, RWR, SP, Endeavour and ToppGene it was 9.6, 9.8, 10, 10.1, 10.5 
and 10.94, respectively. Table 4 also shows that in leave-one-out cross-validation 
analysis, 28% of the seed genes were achieved the highest ranking (top 1%) among genes 
in their related artificial linkage interval by using the HybridRanker which in comparison 
to other methods is the highest percentage. In addition, HybridRanker has the greatest 
percentage of the seed genes those are ranked in top 5% among genes in their related 
intervals. Furthermore, the results in Table 4 show that our method had the largest MMR 
value among all methods. Overally, all used criteria showed the better performanc of 
HybridRanker comparing to other examined algorithms. 
 
Table 4. Different criteria for evaluating different disease gene prioritization methods. 
Methods AUC MRR Average rank 1% 5% 
HybridRanker 0.95 0.46 5.28 0.28 0.72 
Endeavour 0.76 0.25 10.5 0.10 0.40 
ToppGene 0.70 0.28 10.94 0.14 0.34 
DIR 0.91 0.28 9.6 0.18 0.38 
RWR 0.90 0.25 10 0.12 0.40 
SP 0.90 0.14 10.1 0 0.18 
NP 0.91 0.25 9.8 0.12 0.40 
 
Additionally, giving the top 100 ranked candidate genes to ClueGO showed that these 
genes were significantly enriched with GO terms and pathways most of which are 
consistent with several studies in CRC (see Table 5). Also, to examine the relevance of 
the obtained GO terms and CRC, we utilized the Comparative Toxicogenomics Database 
(CTD) [30]. Inferred associations between GO terms and diseases are provided in the 
CTD. We found that among GO terms listed in Table 5, four terms included negative 
 regulation of DNA replication, response to UV, ovulation cycle process and stem cell 
proliferation are associated with CRC. 
 
 
Figure 3. The ROC curves for HybridRanker and all other examined ones. 
 
We also investigate the interactions between the top 100 ranked candidate genes and the 
seed genes. For each top gene, the lengths of shortest paths to all seed genes were 
computed and the minimum value of these lengths was considered. The results showed 
that 96% of these top genes were at the distance at most two from a seed gene (83% of 
them had direct interactions). Also, we found out that there were 3638 genes that 
participated in the shortest paths between the top genes and the seed ones. Among these 
intermediate genes, ten genes participated in the shortest paths between top candidates 
and seed genes, for more than a thousand times (listed in Table 6). In addition, the results 
showed that 99% (1112 out of 1121) of the seed genes had direct interactions to the top 
ranked candidate genes. 
For further analysis, we examined the expressions of the top 100 ranked candidate genes 
in an expression dataset of CRC samples. The dataset used in this paper was obtained 
from Gene Expression Omnibus (GEO) database [43] at accession number GSE32323 
(with 17 pairs of cancer and non-cancerous tissues from CRC patients). We used Mann-
Whitney test to identify genes that were differentially expressed. The results showed that 
46 of the top candidate genes were differentially expressed between normal and tumor 
tissues (p-value<0.05). 
 
Table 5. Related Go terms and pathways to the top 100 ranked candidate genes in HybridRanker which most of 
them are consistent with several studies in CRC. 
GO/Pathway ID GO/Pathway Term Paper 
WP:24 Peptide GPCRs [31] 
GO:0000245 spliceosome complex assembly [32] 
GO:0007189 adenylate cyclase-activating G-protein coupled 
receptor signaling pathway 
[33] 
GO:0008156 negative regulation of DNA replication [34] 
GO:0008589 regulation of smoothened signaling pathway [35] 
GO:0009411 response to UV [36] 
GO:0010107 potassium ion import [37] 
GO:0022602 ovulation cycle process  
GO:0034367 macromolecular complex remodeling [38] 
GO:0045834 positive regulation of lipid metabolic process [39] 
GO:0045913 positive regulation of carbohydrate metabolic 
process 
[40] 
GO:0072089 stem cell proliferation [41] 
GO:1904036 negative regulation of epithelial cell apoptotic 
process 
[42] 
 
 
Table 6. The genes which are mediate in shortest paths between the top 100 ranked candidate genes of 
HybridRanker and seed genes for more than 1000 times. 
Gene symbol 
PYGL 
RNPEP 
CMA1 
PLCXD3 
TRABD 
GSR 
BARHL2 
ORC5 
TRPM1 
HINT1 
 
 4.   Discussion 
 
In this paper, HybridRanker method is proposed as a new prioritization method to 
overcome disadvantages of pure network-based methods. The HybridRanker integrated 
information about disease similarity, disease comorbidity and phenotype similarity with 
human PPI network to utilize the advantages of both biological knowledge and network 
topological features. Similar phenotypes are assumed to be associated with the same 
causing genes [44, 45]. Based on that, we exploited two kinds of data in scoring new 
candiate disease genes: (1) known causing genes of diseases with similar symptoms to 
CRC and (2) genes related to the phenotypes similar to the CRC phenotypes. Also, 
disease comorbidity gives another important information which has been rarely 
considered in gene prioritization studies. Besides, there is an accepted assumption that 
disease proteins tend to have interactions with each other [46]. So, in HybridRanker we 
combined all these knowledge to gain better results in cancer gene prioritization. 
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